Brief report on a phase I/IIa study to assess the safety, tolerability, and immune response of AGMG0201 in patients with essential hypertension

We have been developing an angiotensin II vaccine for hypertension. We conducted a placebo-controlled dose escalation study to investigate the safety, tolerability, and immunological responses of this angiotensin II vaccine (AGMG0201). AGMG0201 was administered to participants with mild to moderate...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakagami, Hironori, Ishihama, Tetsuya, Daikyoji, Yuichi, Sasakura, Chieka, Yamada, Ei, Morishita, Ryuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668431/
https://www.ncbi.nlm.nih.gov/pubmed/34657138
http://dx.doi.org/10.1038/s41440-021-00755-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668431/
https://www.ncbi.nlm.nih.gov/pubmed/34657138
http://dx.doi.org/10.1038/s41440-021-00755-6

Ejemplares similares